By: IPP Bureau
Last updated : May 22, 2026 6:21 pm
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Sun Pharmaceutical Industries Limited reported a strong performance for Q4 and full year FY26, driven by robust growth in its India formulations business and continued momentum in Innovative Medicines.
The company posted Q4FY26 consolidated sales of Rs. 145,598 million, registering a 13.6% year-on-year growth, while net profit rose 26.2% to Rs. 27,140 million. EBITDA for the quarter stood at Rs. 39,542 million with an EBITDA margin of 27.1%.
For the full year FY26, Sun Pharma reported consolidated sales of Rs. 582,201 million, up 11.9% YoY, while net profit increased 5% to Rs. 114,794 million. EBITDA rose 16.1% to Rs. 177,314 million, with EBITDA margin improving to 30.3%.
The company’s Global Innovative Medicines business continued to emerge as a key growth engine, with Q4 sales rising 20.1% to US$ 354 million and full-year sales reaching US$ 1.42 billion. Innovative Medicines contributed 22.2% of Q4 sales and 20.7% of FY26 sales.
India formulations remained a major contributor, with Q4 sales growing 14.8% to Rs. 48,359 million. Sun Pharma strengthened its leadership position in the domestic market, increasing market share from 8.1% to 8.4%, according to Pharmarack MAT March 2026 data. The company launched 37 new products during FY26.
The US formulations business reported quarterly sales of US$ 459 million, marginally lower by 1.1%, as growth in Innovative Medicines offset weakness in the generics segment. Emerging Markets and Rest of World businesses delivered healthy double-digit growth during the year.
API sales also showed strong momentum during the quarter, rising 26.4% to Rs. 6,739 million.
On the R&D front, Sun Pharma invested Rs. 35,540 million during FY26, accounting for 6.1% of sales. The company currently has five novel entities in clinical development, 552 approved ANDAs in the US, and 57 approved NDAs.
Kirti Ganorkar, Managing Director of Sun Pharma, said, “The company achieved its highest India market share gain since the Ranbaxy acquisition, while the US Innovative Medicines business crossed the US$ 1 billion revenue milestone.”
“The recently announced acquisition of Organon assets is expected to further accelerate Sun Pharma’s transformation into a leading global pharmaceutical company,” Ganorkar added further.